Enhancement of A spermatogonial proliferation and differentiation in irradiated rats by gonadotropin-releasing hormone antagonist administration.

Shuttlesworth GA, de Rooij DG, Huhtaniemi I, Reissmann T, Russell LD, Shetty G, Wilson G, Meistrich ML

Endocrinology1 Jan 2000Cited by 74 (Europe PMC)

PMID10614621DOI10.1210/endo.141.1.7272PepBankPUB-10614621

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In irradiated rats, cetrorelix reduced intratesticular testosterone to 6% of irradiated-control levels within 1 week.
In plain wordsIn rats, cetrorelix reduced intratesticular testosterone to 6% of irradiated-control levels within 1 week.
Peptide
Cetrorelix
Outcome
DecreaseIntratesticular testosterone
Study
ratn: not reported in source
Irradiated LBNF1 rats
Comparator
Irradiated rats without hormone treatment
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Intratesticular testosterone
6 % of irradiated control
within 1 week
Source sentences
Summary
Hormone administration decreased the intratesticular testosterone concentration to 6% of the level in irradiated rats within 1 week.
1 context sentence(design, population, supporting numbers)
Summary · context
LBNF1 rats were given 6 Gy of gamma-irradiation; some were treated with the GnRH antagonist Cetrorelix beginning 15 weeks after irradiation.
Report a problemFND-1061462101
02AnimalAnimal study (in vivo)Efficacy outcome
In irradiated rats, cetrorelix reduced spermatogonial apoptotic indexes to 43% of irradiated-only levels.
In plain wordsIn rats, cetrorelix reduced spermatogonial apoptotic indexes to 43% of irradiated-only levels.
Peptide
Cetrorelix
Outcome
DecreaseSpermatogonial apoptotic indexes
Study
ratn: not reported in source
Irradiated LBNF1 rats
Comparator
Irradiated rats without hormone treatment
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Apoptotic indexes
43 % of irradiated-only levels
reported result
Source sentences
Summary
Concomitantly, there was a decrease in spermatogonial apoptotic indexes to 43% of levels in irradiated-only rats, leading to an increases in their numbers by 150%, their diameters by 11%, and their labeling indexes by 31%.
1 context sentence(design, population, supporting numbers)
Summary · context
LBNF1 rats were given 6 Gy of gamma-irradiation; some were treated with the GnRH antagonist Cetrorelix beginning 15 weeks after irradiation.
Report a problemFND-1061462102
03AnimalAnimal study (in vivo)Efficacy outcome
In irradiated rats, cetrorelix increased spermatogonial numbers by 150% relative to irradiated-only rats.
In plain wordsIn rats, cetrorelix increased spermatogonial numbers by 150% relative to irradiated-only rats.
Peptide
Cetrorelix
Outcome
IncreaseSpermatogonial numbers
Study
ratn: not reported in source
Irradiated LBNF1 rats
Comparator
Irradiated rats without hormone treatment
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Spermatogonial number increase
150%
reported result
Source sentences
Summary
Concomitantly, there was a decrease in spermatogonial apoptotic indexes to 43% of levels in irradiated-only rats, leading to an increases in their numbers by 150%, their diameters by 11%, and their labeling indexes by 31%.
1 context sentence(design, population, supporting numbers)
Summary · context
LBNF1 rats were given 6 Gy of gamma-irradiation; some were treated with the GnRH antagonist Cetrorelix beginning 15 weeks after irradiation.
Report a problemFND-1061462103
04AnimalAnimal study (in vivo)Efficacy outcome
In irradiated rats, cetrorelix increased spermatogonial diameters by 11% relative to irradiated-only rats.
In plain wordsIn rats, cetrorelix increased spermatogonial diameters by 11% relative to irradiated-only rats.
Peptide
Cetrorelix
Outcome
IncreaseSpermatogonial diameters
Study
ratn: not reported in source
Irradiated LBNF1 rats
Comparator
Irradiated rats without hormone treatment
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Spermatogonial diameter increase
11%
reported result
Source sentences
Summary
Concomitantly, there was a decrease in spermatogonial apoptotic indexes to 43% of levels in irradiated-only rats, leading to an increases in their numbers by 150%, their diameters by 11%, and their labeling indexes by 31%.
1 context sentence(design, population, supporting numbers)
Summary · context
LBNF1 rats were given 6 Gy of gamma-irradiation; some were treated with the GnRH antagonist Cetrorelix beginning 15 weeks after irradiation.
Report a problemFND-1061462104
05AnimalAnimal study (in vivo)Efficacy outcome
In irradiated rats, cetrorelix increased spermatogonial labeling indexes by 31% relative to irradiated-only rats.
In plain wordsIn rats, cetrorelix increased spermatogonial labeling indexes by 31% relative to irradiated-only rats.
Peptide
Cetrorelix
Outcome
IncreaseSpermatogonial labeling indexes
Study
ratn: not reported in source
Irradiated LBNF1 rats
Comparator
Irradiated rats without hormone treatment
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Labeling index increase
31%
reported result
Source sentences
Summary
Concomitantly, there was a decrease in spermatogonial apoptotic indexes to 43% of levels in irradiated-only rats, leading to an increases in their numbers by 150%, their diameters by 11%, and their labeling indexes by 31%.
1 context sentence(design, population, supporting numbers)
Summary · context
LBNF1 rats were given 6 Gy of gamma-irradiation; some were treated with the GnRH antagonist Cetrorelix beginning 15 weeks after irradiation.
Report a problemFND-1061462105
06AnimalAnimal study (in vivo)Efficacy outcome
In irradiated rats receiving cetrorelix, mitotic clones gradually enlarged, with clones exceeding eight cells at week 3.
In plain wordsIn rats receiving cetrorelix after irradiation, mitotic clones gradually enlarged, with clones exceeding eight cells at week 3.
Peptide
Cetrorelix
Outcome
IncreaseMitotic clone sizes
Study
ratn: not reported in source
Irradiated LBNF1 rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
The sizes of the mitotic clones gradually increased, and clones of more than eight cells appeared at week 3 of hormone treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
LBNF1 rats were given 6 Gy of gamma-irradiation; some were treated with the GnRH antagonist Cetrorelix beginning 15 weeks after irradiation.
Report a problemFND-1061462106
07AnimalAnimal study (in vivo)Efficacy outcome
In irradiated rats receiving cetrorelix, differentiation began at week 4 and involved 30% of tubules by week 6.6.
In plain wordsIn rats receiving cetrorelix after irradiation, differentiation began at week 4 and involved 30% of tubules by week 6.6.
Peptide
Cetrorelix
Outcome
IncreaseSpermatogonial differentiation
Study
ratn: not reported in source
Irradiated LBNF1 rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Tubules with differentiation
30%
week 6.6
Source sentences
Summary
A spermatogonial differentiation began at week 4, and by week 6.6, differentiation occurred in 30% of the tubules.
1 context sentence(design, population, supporting numbers)
Summary · context
LBNF1 rats were given 6 Gy of gamma-irradiation; some were treated with the GnRH antagonist Cetrorelix beginning 15 weeks after irradiation.
Report a problemFND-1061462107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.